Revolution Medicines (NASDAQ:RVMD – Get Free Report) had its target price hoisted by stock analysts at Oppenheimer from $43.00 to $45.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s target price suggests a potential upside of 20.29% from the […]
As of April 12, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) had its target price upped by Oppenheimer from $43.00 to $45.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Oppenheimer’s price target points to a potential upside of 20.29% from the company’s current […]
Revolution Medicines (NASDAQ:RVMD – Get Free Report)‘s stock had its “buy” rating reissued by Needham & Company LLC in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $36.00 target price on the stock. Needham & Company LLC’s target price would indicate a potential upside of 9.12% from […]
Revolution Medicines (NASDAQ:RVMD – Get Free Report) was upgraded by equities research analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a note issued to investors on Wednesday, MarketBeat reports. The brokerage presently has a $48.00 target price on the stock, up from their prior target price of $36.00. Raymond James’ […]